RB nr 70/2008

Legal basis: Art. § 5 subpar. 1 pt. 1 of RO and § 7 of RO

The Management Board of MCI Management S.A. informs that on November 13, 2008 MCI.BioVentures Sp. z o.o. – a subsidiary of MCI Management SA – paid in the capital to take up 375 new shares with their nominal value of PLN 100 per share in 24med sp. z o.o. MCI.BioVentures paid PLN 600,000 in cash for the purchased shares that is PLN 1,600 per share. As a result of the subscription of new shares MCI.BioVentures holds 42.8% of the share capital in 24med Sp. z o.o.

The transaction was made in connection with the fulfillment of the conditions of the investment agreement concluded between MCI.BioVentures and 24med on Sept. 22, 2008 and it means the scheduled completion of the 1st round of financing.

24med is a company whose operations consists in providing subscription medical services including emergency medical aid as well as ambulatory care and imaging diagnostics. MCI.BioVentures is a seed capital fund investing up to EUR 1 million in companies operating in sectors of biotechnology, new drugs and healthcare in Poland. The funds of the fund shall be spent on the investments in the companies at their early stage of growth.

This is a long-term investment. There are no connections referred to in § 7 subpar. 6 of RO. The purchased assets represent over 20% of the share capital in 24med Sp. z o.o. and they are considered assets of considerable value.